Project Abstract

This project aims to develop a novel transdermal drug delivery system that can enhance the bioavailability of therapeutic compounds, addressing the limitations of conventional oral and parenteral administration routes. Transdermal drug delivery offers several advantages, including improved patient compliance, reduced side effects, and the ability to bypass first-pass metabolism in the liver. However, the skin's inherent barrier properties, particularly the stratum corneum, often hinder the effective permeation of drugs, limiting the potential of transdermal administration. The primary objective of this project is to design and fabricate a transdermal drug delivery system that can efficiently deliver active pharmaceutical ingredients (APIs) across the skin barrier, leading to enhanced bioavailability and therapeutic efficacy. This will be achieved through the development of a novel drug delivery platform that incorporates innovative strategies to overcome the skin's barrier function, such as the use of chemical enhancers, physical techniques, or a combination thereof. The project will begin with a comprehensive literature review to identify the current state-of-the-art in transdermal drug delivery and the challenges associated with improving drug bioavailability. This will inform the selection of the most promising approaches to enhance skin permeation, which will then be investigated and optimized through a systematic experimental process. The experimental work will involve the formulation and characterization of the transdermal drug delivery system, including the selection of suitable excipients, the optimization of drug loading, and the evaluation of physicochemical properties. In-vitro studies will be conducted to assess the drug release kinetics, skin permeation, and the effectiveness of the delivery system in overcoming the skin barrier. This will include the use of advanced skin models, such as artificial or human-derived skin equivalents, to closely mimic the in-vivo conditions. Furthermore, the project will employ advanced analytical techniques, such as high-performance liquid chromatography (HPLC), mass spectrometry, and spectroscopic methods, to quantify the drug concentrations in the skin layers and in the systemic circulation, allowing for the evaluation of the system's bioavailability and pharmacokinetic profile. Depending on the outcome of the in-vitro studies, the project may progress to in-vivo animal studies to assess the safety, tolerability, and efficacy of the developed transdermal drug delivery system. This will involve the use of appropriate animal models and the measurement of relevant pharmacological and toxicological endpoints. The successful completion of this project will result in the development of a novel transdermal drug delivery platform that can significantly enhance the bioavailability of therapeutic compounds, leading to improved patient outcomes and reduced side effects. The outcomes of this research could have a substantial impact on the pharmaceutical industry, as it may enable the effective transdermal delivery of a wider range of drugs, including those that were previously considered unsuitable for this administration route. Furthermore, the innovative strategies and methodologies developed during this project can potentially be applied to the design of other advanced drug delivery systems, contributing to the broader field of pharmaceutical technology and drug formulation.

Project Overview